In 5-10% of patients, neurofibromatosis type 1 (NF1) results from microdeletions that encompass the entire NF1 gene and a variable number of flanking genes. Two recurrent microdeletion types are found in most cases, with microdeletion breakpoints located in paralogous regions flanking NF1 (proximal NF1-REP-a and distal NF1-REP-c for the 1.4 Mb type-1 microdeletion, and SUZ12 and SUZ12P for the 1.2 Mb type-2 microdeletion). A more severe phenotype is usually associated with NF1 microdeletion patients than in those with intragenic mutations. We characterized NF1 microdeletions in 70 unrelated NF1 microdeleted patients using a high-resolution NF1 custom array comparative genomic hybridization (CGH). Genotypephenotype correlations were studied in 58 of these microdeletion patients and compared to 389 patients with intragenic truncating NF1 mutations and phenotyped in the same standardized way. Our results confirmed in an unbiased manner the existence of a contiguous gene syndrome with a significantly higher incidence of learning disabilities and facial dysmorphism in microdeleted OFFICIAL JOURNAL www.hgvs.org Comment [c1]: Please provide the first name and affiliation for this author.
patients compared to patients with intragenic NF1 mutations. Microdeleted NF1 patients also showed a trend toward significance for childhood overgrowth. High-resolution array-CGH identified a new recurrent ~1.0 Mb microdeletion type, designated as type-3, with breakpoints in the paralogous regions middle NF1-REP-b and distal NF1-REP-c. ©2010 Wiley-Liss, Inc.
INTRODUCTION
Neurofibromatosis type 1 (NF1; MIM# 162200) is an autosomal disorder with an estimated incidence of 1 in 3500 live births (Carey et al., 1986) . NF1 is due to autosomal dominant loss-of-function mutations of the NF1 gene (neurofibromin 1; NM_000267), a tumour suppressor gene located at 17q11.2 and containing 60 translated exons distributed over ~300 kb. In 5-10% of patients, NF1 is caused by genomic microdeletions that encompass the entire NF1 gene and a variable number of immediately flanking genes . The majority of such NF1 patients have one of two recurrent types: type-1 and type-2 microdeletions. The typical type-1 microdeletion is 1.4 Mb long, contains NF1 and at least 14 additional protein-coding genes, four pseudogenes and two microRNAs (Supp. Figure S1 ) and is caused by non-allelic homologous recombination (NAHR) between paralogous sequences flanking the NF1 gene: the NF1 proximal and distal low-copy repeats (LCRs): NF1-REP-a and NF1- REP-c (Dorchner et al., 2000; López Correa et al., 2000; Jenne et al., 2001 Jenne et al., , 2003 Forbes et al., 2004; Raedt et al., 2006) . The typical type-2 microdeletion is smaller (1.2 Mb) and has breakpoints located in the SUZ12 gene (suppressor of zeste 12 homolog; NM_015355) and its pseudogene SUZ12P (Petek et al., 2003; Kehrer-Sawatzki et al., 2004; Steinmann et al., 2007; Roehl et al., 2010) . Even less frequent, atypical NF1 microdeletions with non-recurring breakpoints have also been reported (Riva et al., 2000; Kehrer-Sawatzki et al., 2003 Venturin et al., 2004a; Mantripragada et al., 2006; Pasmant et al., 2008) .
The main features of NF1 include multiple café-au-lait (CAL) spots, skin-fold freckling, Lisch nodules, and benign peripheral nerve sheath tumours (dermal and plexiform neurofibromas) whose occurrence, number, and size vary greatly from one patient to another, even from within the same NF1 family (Friedman, 1999) . More than half of NF1 patients will also develop plexiform neurofibromas, of which about 5-10% will progress into a malignant peripheral nerve sheath tumour (MPNST) (Evans et al., 2002) .
While NF1 represents a simply determined Mendelian disorder with complete penetrance, it is however characterized by highly variable expressivity in both the number of major features and the occurrence of complications (Friedman, 1999; Sabbagh et al., 2009) . A more severe clinical phenotype has been reported in NF1 patients carrying genomic microdeletions that involve the entire NF1 gene, compare to patients with intragenic NF1 mutations. This contiguous gene syndrome does appear to include dysmorphic features (Upadhyaya et al., 1998; López Correa et al., 1999 , 2000 Streubel et al., 1999; Riva et al., 2000; Castle et al., 2003; Venturin et al., 2004b) , learning disabilities (Tonsgard et al., 1997; Upadhyaya et al., 1998; Korf et al., 1999; López Correa et al., 1999 , 2000 Streubel et al., 1999; Riva et al., 2000; Castle et al., 2003; Descheemaeker et al., 2004; Venturin et al., 2004b) , cardiovascular malformations (Riva et al., 2000; Venturin et al., 2004b Venturin et al., , 2005 Mensink et al., 2006) , childhood overgrowth (Spiegel et al., 2005) , a higher tumour burden and earlier onset of benign neurofibromas (Leppig et al., 1997; López Correa et al., 2000; Castle et al., 2003) , and probably, a higher incidence of MPNSTs (De Raedt et al., 2003) and other malignancies (López Correa et al., 2000) . While many reports of NF1 microdeleted patients (currently > 150 cases) (Mensink et al., 2006) have been published since the initial study in 1992 (Kayes et al., 1992) , to date, little is known about this genotype-phenotype correlation. The limited number of microdeletions characterized per study, the imprecise definition of their boundaries, and the lack of appropriate control patients, had made it difficult to establish reliable genotype-phenotype correlations.
To further explore the different NF1 locus rearrangements, and the putative association with such a contiguous gene syndrome phenotype, a large cohort of 70 unrelated NF1 microdeleted patients was studied. Their microdeletions were accurately characterized using a high-resolution NF1 custom array comparative genomic hybridization (CGH) targeting the 17q11.2 region. The genotype-phenotype correlation in 58 of these microdeletion patients was statistically evaluated, taking 389 unrelated patients with intragenic NF1 truncating mutations as a reference group. All NF1 patients were clinically assessed utilising the same standardized 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 questionnaire collection protocol. Our results demonstrate that NF1 microdeletion patients have a significantly higher incidence of learning disabilities and facial dysmorphism than patients with intragenic NF1 mutation, after adjusting for age and sex.
Human Mutation

MATERIAL AND METHODS
Study samples
A initial panel of 21 NF1 microdeleted patients was identified through a comprehensive mutation screening of 561 NF1 index cases, enrolled between 2002 and 2005 in the French Clinical Research Program entitled "Study of expressivity of neurofibromatosis 1: constitution of a phenotype-genotype database" (coordinator: Pr. P. Wolkenstein, Henri Mondor Hospital, Créteil, France) to constitute the so-called 'NF-France database', as previously described (Sabbagh et al. 2008) . The mutation screening of the NF1 gene was performed using a variety of NF1 gene screening methodologies that included, DNA and RNA sequencing, for small lesions, polymorphic microsatellite marker analysis and multiplex ligation-dependent probe amplification (MLPA) or real-time PCRbased gene-dosage analysis to permit microdeletion assessment, as previously described (Pasmant et al., 2008; Upadhyaya et al., 2008) . Among the 561 NF1 index cases, 512 individuals presented a NF1 alteration, 2 showed a SPRED1 (sprouty-related, EVH1 domain containing 1; NM_152594) mutation, and no NF1 and SPRED1 mutation was identified in the 47 remaining patients, as previously described (Pasmant et al., 2009b) . Among the 512 index cases with a fully characterized NF1 mutation, 21 patients (4%) presented a NF1 microdeletion, in accordance with previous data . A second cohort of 49 NF1 microdeleted patients was selected from routine NF1 genotyping at Beaujon Hospital (Clichy, France) and at Institute of Medical Genetics (Cardiff, UK).
In total, 70 unrelated NF1 patients harbouring a NF1 microdeletion were included in this present study, of which 50 patients (79%) had a de novo microdeletion and 13 patients (21%) had inherited their microdeletion. Relevant inheritance data was unavailable for the remaining 7 patients.
The reference control group for this genotype-phenotype correlation study involved the use of non-deleted NF1 patients with characterized NF1 intragenic truncating mutations selected from the NF-France database. Only patients with constitutional NF1 nonsense or frameshift mutations were included as it is assumed all such mutations would lead to the premature truncation of neurofibromin. A total of 389 NF1 patients met this criterion and were included in the reference group of non-deleted patients. Patients with missense mutations, in-frame deletions or insertions were excluded from analyses since the functional consequences of such mutations are difficult to assess without functional studies. The 389 patients NF1 molecular alterations were characterized in the same laboratory (Beaujon Hospital, Clichy, France).
For the 70 microdeleted and 389 non-deleted NF1 patients, the full clinical available information was recorded utilising a standardized questionnaire. All patients included in this study fulfilled the National Institutes of Health (NIH) diagnostic criteria for NF1 (Ferner et al., 2007) and their written informed consent was obtained.
Phenotypes
Fourteen major clinical features of NF1 were selected for consideration for the genotype-phenotype association study, as previously described (Sabbagh et al., 2008) . Four were quantitative traits: number of CAL spots (a continuous variable), number of plexiform neurofibromas (a continuous variable), and number of cutaneous and subcutaneous neurofibromas (each classified into one of four semi quantitative categories based on the number of neurofibromas: 0, 1-9, 10-99 and ≥ 100). The other ten clinical features were coded as binary variables: presence/absence of skin-fold freckling, blue-red macules, Lisch nodules, macrocephaly, childhood overgrowth, facial dysmorphism, scoliosis, learning disabilities, optic gliomas, and MPNST development. Patients with missing data for a particular feature were coded as "unknown", and were not then considered in models involving that feature. Most features were identified by physical examination, with Lisch nodules being diagnosed, or excluded, by slit-lamp examination; individuals not given a slit lamp examination were coded as "unknown". The presence or absence of optic gliomas was determined by cranial MRI or CT examination with individuals not given cranial imaging being coded as "unknown". Childhood overgrowth was evaluated only in NF1 patients under the age of 18 and was defined as height and/or head circumference at least two standard deviations above the age-and sexmatched population mean. A facial dysmorphism was diagnosed if two or more of the following signs were observed: coarse face, flat occiput/brachycephaly, facial asymmetry, prominent forehead, frontal bossing, ptosis,
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John Wiley & Sons, Inc. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 downslanting deep set eyes, eversion of the lateral eyelid, epicanthic folds, high and broad nasal bridge, bulbous nasal tip, large and low set ears, malar hypoplasia, wide and prominent philtrum, micrognathia, small pointed chin and low posterior hairline. For scoliosis, only scoliotic curves of >10° were taken into account in our analysis. The diagnosis of learning disabilities was performed on specific testing of cognitive abilities and/or history of scholar difficulties leading to repeating at least one level. Learning deficits most frequently involved visual spatial, visual motor integration skills and language-based skills. The prevalence of many other clinical abnormalities (epilepsy, hydrocephalus, medullary compression by neurofibroma, cerebrovascular complications, renal artery stenosis, pseudoarthrosis, congenital pseudarthrosis of the tibia, dysplastic vertebrae, sphenoid wing dysplasia, xanthogranuloma) were too low (≤ 5%) for meaningful statistical analysis.
Human Mutation
The 70 microdeletion and the 389 control patients' phenotypes, collected through a standardized NF1 questionnaire have been deposited in NCBI's Gene Expression Omnibus (GEO) (Edgar et al., 2002) and are accessible through GEO accession number GSE19730 (at: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19730).
Characterization of NF1 microdeletions
The 70 NF1 patients' microdeletions were accurately characterized by using a custom high-resolution oligonucleotide array-CGH targeting the 17q11.2 region. The theoretical (design) and practical aspects (procedure) of this custom array-CGH are described in detail elsewhere (Pasmant et al., 2009a) . Briefly, we designed a specific array-CGH for the NF1 gene and its flanking regions by using the custom Agilent Human Genome 15K Microarray (Agilent Technologies, Santa Clara, CA, USA). The array comprised a total of 14,207 oligonucleotide probes spanning the whole of chromosome 17, including 12 314 probes spanning a ~8 Mb interval surrounding the NF1 locus (~300 kb). This 8-Mb interval spanned the NF1 gene region and included the largest NF1 atypical microdeletions described in the literature (Riva P et al., 2000; Kehrer-Sawatzki et al., 2003; Venturin et al., 2004a; Pasmant et al., 2008) . Details of the microarray design, including the 14,207 oligonucleotide probe chromosome locations, has been deposited in NCBI's GEO (Edgar et al., 2002) and are accessible through the GEO accession number GSE19730.
Statistical Analysis
Multiple logistic regression was performed to test the association of each clinical feature individually with the type of constitutional NF1 mutation (microdeletion vs. intragenic mutation). Each regression model had the covariates of sex and age at examination (as a continuous variable) to control for potential confounding. Odds ratios (OR) and 95% confidence intervals (CI) were also calculated when appropriate. We applied the Bonferroni correction, by which the nominal alpha value is adjusted based upon the number of tests performed, to account for multiple testing. All statistical analyses were performed with StatView 5.0 software (Cary, NC).
RESULTS
Array-CGH characterization of the 70 NF1 microdeletions
All 70 NF1 microdeletions were accurately characterized with our NF1 customised array-CGH platform and consisted of 77% type-1 (54/70), 9% type-2 (6/70), 4% type-3 (new recurrent type) (3/70), and 10% atypical microdeletions (7/70) (Table 1 ). An estimation of the length of each microdeletion as well as their gene content, was obtained by using the know locations of the last proximal and first distal non-deleted probes (Table 1; Supp.  Table S1 ). A new recurrent ~1.0 Mb microdeletion type, designated here as type-3 microdeletion, was identified in three unrelated NF1 patients (GUE, OLI, and N2603), involving NF1-REP-b (but not NF1-REP-a) and NF1-REPc. Figure 1 shows the relevant array-CGH profiles for the three recurrent types. The 14,207 array-CGH log2 normalized ratio data of the 70 patients discussed in this publication have been deposited in NCBI's GEO (Edgar et al., 2002) and are accessible through GEO accession number GSE19730 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19730). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Genotype-phenotype correlations
From the 70 microdeleted NF1 patients, 12 individuals were excluded from the statistical analysis of genotypephenotype correlations: two had the largest atypical microdeletions (DUB: 7.6 Mb and N806: 5.5 Mb), and 10 patients had incomplete phenotype data. In the 58 remaining patients (27 men [46%] and 31 women [53%], mean age at examination = 20.5 ± 17.6 years), there were 44 type-1, 6 type-2, 3 type-3, and 5 atypical microdeletions. The reference group of non-deleted NF1 patients with intragenic truncating mutations (n=389) consisted of 169 men (43%) and 220 women (57%) with a mean age at examination of 33.2 ± 13.9 years.
The clinical characteristics associated with the non-deleted, the microdeleted, and the only type-1 microdeleted NF1 patients, are provided in Table 2 . The prevalence of the different clinical features in non-deleted patients is comparable to previously reported features for the general NF1 population (Huson and Huges, 1994; Friedman and Birch, 1997; North, 2000) . When compared to this reference group, the microdeleted patients as a whole (n = 58), had a significantly higher incidence of dysmorphic features (52% vs. 11%, P < 0.0001, OR = 5.3 [2.7-10.4]) and learning disabilities (80% vs. 52%, P = 0.001, OR = 3.3 [1.6-6.7]) at the Bonferroni-corrected significance threshold of 0.004 (0.05 divided by 14 for 14 traits tested individually), after adjusting for age and sex ( childhood overgrowth was observed when the microdeleted patients were considered as a whole, with this characteristic found to be overrepresented in microdeleted patients compared to non-deleted cases (30% vs. 6%, P = 0.005, ). This association was however not statistically significant after applying the conservative Bonferroni correction for multiple comparisons. No significant associations were observed for any other clinical features. The apparently higher incidence of cutaneous neurofibromas in non-deleted patients, as compared to microdeleted patients (78% vs. 51%, respectively), is easily explainable by the greater proportion of prepubertal children (< 10 years old) in the latter group (36% vs. 6%). The association of this trait with the presence of an NF1 microdeletion was indeed not significant (P = 0.57) when the effect of age was properly taken into account in the multiple regression analysis by using age as a covariate.
The proportion of de novo cases (which may contain some cases of mosaicism) was significantly higher in microdeleted patients compared to patients with intragenic mutations (79% vs. 43%, Chi Square test, P value < 0.0001). Therefore, somatic mosaicism has to be taken into account in the evaluation of genotype-phenotype correlations as it could explain some of the observed differences between the two groups of patients. However, when the nature (inherited or sporadic) of the NF1 mutation was introduced in the multiple regression models as a covariate, along with sex and age at examination, the associations of facial dysmorphism and learning disabilities with NF1 microdeletions (all pooled together) were still significant (P < 0.0001, .0] for facial dysmorphism, and P = 0.002, OR = 3.4 [1.5-7.3] for learning disabilities). Significant results were also observed when only the type-1 microdeleted patients were considered (P = 0.0001, OR = 4.9 [2.2-11.1] for facial dysmorphism, and P = 0.001, OR = 5.6 [2.0-15.7] for learning disabilities). Therefore, the association of facial dysmorphism and learning disabilities with NF1 microdeletions is unlikely to result from the presence of unknown cases of mosaicism in our group of NF1 patients.
DISCUSSION
The extreme variability of clinical expression in NF1 makes difficult genotype-phenotype correlation, although they are of crucial importance for patients and their families. Hence, solid evidence for the existence of a microdeletion syndrome has awaited a comprehensive phenotype and genotype evaluation of a cohort of NF1 microdeletion subjects ascertained in an unbiased manner and compared with an appropriate reference population phenotypically evaluated in the same standardized way as microdeleted patients.
The 70 newly characterized NF1 microdeletion patients described here, the largest cohort ever reported, with the exception of meta-analysis from the published literature (Venturin et al., 2004b) , has been both genotyped with an ad hoc array-CGH platform, and clinically phenotyped utilising a standardized questionnaire. The microdeletion patients were compared to 389 patients with NF1 diagnosed according to the NIH clinical criteria and presenting intragenic NF1 truncating mutations. NF1 patients with NF1 missense mutations, with no NF1 mutations, and with SPRED1 mutations were excluded as the NIH criteria cannot reliably distinguish NF1 from NF1-like syndrome caused by SPRED1 mutations (NFLS; MIM# 611431) (Pasmant et al. 2009b; Spurlock et al., 2009; Messiaen et al., 2009 ). This selection allowed comparing clinical phenotype consequences of NF1 locus microdeletions versus the sole NF1 gene haploinsufficiency (intragenic truncating mutations).
In contrast to previous molecular or cytogenetic techniques, such as multiplex ligation-dependent probe amplification or fluorescence in situ hybridization, our customised array-CGH platform was able to unambiguously differentiate and characterize NF1 microdeletion types (De Luca et al., 2007; Pasmant et al., 2009a) . Notably, the high-resolution of the array-CGH has allowed identification of a new recurrent NF1 microdeletion type, designated as type-3, with breakpoints in the paralogous regions middle NF1-REP-b and distal NF1-REP-c (Figure 1) . The most common type-1 microdeletion involved two paralogous sequences flanking the NF1 gene: NF1 proximal and distal LCR (NF1-REP-a and NF1-REP-c). A middle LCR (namely NF1-REP-b) has been previously identified between NF1-REP-a and the NF1 gene Forbes et al., 2004; ) (Supp. Figure S1 ). These three LCR blocks (NF1-REP-a, b, and c) belong to a complex group of paralogs with three components on 17q11.2 (i.e. in the NF1 microdeletion region: NF1-REP-a, b, and c) , six at 17q21 (NF1 -REP-d, e, f, g, h, and i) , one at 17q24 (NF1-REP-j), and another on 19p13 (De . Interestingly, a genomic microdeletion caused by NAHR between the NF1-REP-a, and NF1-REP-b repeats and which included RNF135 and five other genes, but not the NF1 gene, has been described in an individual with an overgrowth syndrome (Douglas et al., 2007) . For the first time, we describe a recurrent type-3 microdeletion in three unrelated NF1 patients (GUE, OLI, and N2603), with breakpoints located in the paralogous sequences NF1- REP-b (located between RNF135 and NF1) and NF1-REP-c (Figure 1) , consistent with NAHR between these NF1 medial and distal LCRs. This type-3 microdeletion is ~1 Mb in size and removed the entire NF1 gene and at least eight other genes: OMG, EVI2B, EVI2A, RAB11FIP4, CR17orf79, UTP6, SUZ12, and LRRC37B, but not LRRC37B2, CRLF3, ATAD5, CENTA2, and RNF135 (Table 1; Supp. Table S1 ). It is worth noting that the three type-3 NF1 microdeletion patients showed facial dysmorphism. Two of them (GUE and OLI) had subcutaneous and plexiform neurofibromas. One of them (GUE) presented learning disabilities while this information was unavailable for N2603 and OLI who were 4 and 3 years old at the examination time, respectively.
The present study confirms in an unbiased manner the existence of a contiguous gene syndrome associated with specific clinical signs in NF1 microdeletion patients. Two NF1 clinical features, learning disabilities and facial dysmorphism show significant association with NF1 microdeletions, after adjusting for multiple comparisons. While this finding is consistent with most previous NF1 microdeletion studies, facial dysmorphism appeared to be much less prevalent in the microdeleted patients herein described than previously reported (52% in this study versus 78% in a meta-analysis of the published literature on the NF1 microdeletions in 78 patients) (Venturin et al., 2004b) . It is noteworthy that the concomitant presence of both learning disabilities and facial dysmorphism was considerably overrepresented in the NF1 microdeleted patients compared to the non-deleted NF1 cases (45% vs. 7%, P < 0.0001, ). Nevertheless, while patients with large deletions of the NF1 locus do have a much greater probability to have learning disabilities and facial dysmorphism, it is still impossible to predict the presence of a NF1 microdeletion based solely on these clinical symtoms, as previously claimed (Tonsgard et al., 1997) . No association between these two clinical features was observed in our group of microdeleted patients (P = 0.45, after adjusting for age and sex), suggesting that different genetic factors may be involved in the determination of each of these traits. Remarkably, haploinsufficiency of OMG gene, mapping in the typical NF1 microdeletion interval, has been proposed to be involved in the learning disabilities found in NF1 microdeletion patients (Venturin et al., 2006) .
Our study also suggests some evidence of an association of childhood overgrowth with NF1 microdeletion, although this was not significant at the Bonferroni-corrected threshold. This observation confirms results published by Spiegel et al. who proposed that overgrowth was indeed a component of the phenotypic spectrum of the NF1 microdeletion syndrome (Spiegel et al., 2005) . RNF135 haploinsufficiency was proposed to be responsible for the overgrowth often observed in individuals with NF1 microdeletions (Douglas et al., 2007) . Interestingly, none of the four microdeleted patients with no RNF135 deletion (i.e. RNF135 not included in the microdeletion interval), NF00234, and three type-3 microdeletion patients (GUE, OLI, and N2603), presented childhood overgrowth. It is also of note that no RNF135 point mutation or deletion has been found in patients with NF1 intragenic truncating mutation and with overgrowth, ruling out a putative double heterozygosity for mutations in both the NF1 and RNF135 genes in these patients (data not shown). Our cohort of NF1 microdeleted patients had twice as many MPNSTs as did the non-deleted patients (6% vs. 3%), in agreement with previous published results (De Raedt et al., 2003) . This finding is however not significant, because of the lack of power from small sample size and the low incidence of this trait. Hence, these two last findings (childhood overgrowth and possibly increased incidence of MPNSTs) warrant be replicated in an independent sample before any conclusions can be drawn.
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Supp. Figure S1 . Schematic representation of the 17q11.2 region. Type-1 1.4 Mb microdeletion encompasses the entire 350-kb NF1 gene, 14 flanking protein-coding genes, four pseudogenes, and two microRNAs. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table S1 . Gene content of the three typical microdeletions and the < 2 Mb atypical microdeletions.
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